High Protein Diet and Atherosclerosis (HPA)
Primary Purpose
Atherosclerosis
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Standard meal
High animal protein meal
High plant protein meal
High plant protein meal with additional leucine
Sponsored by
About this trial
This is an interventional other trial for Atherosclerosis
Eligibility Criteria
Inclusion Criteria:
- >=45 and <=75 years of age
- body mass index >=25.0 and <40.0 kg/m2
Exclusion Criteria:
- <45 and >75 years of age
- body mass index <25.0 or >39.9 kg/m2
- plasma triglyceride <150 mg/dl
- LDL-cholesterol <130 mg/dl
- HDL-cholesterol ≥40 mg/dl in men and ≥50 mg/dl in women
- history of or current significant organ system dysfunction
- allergies or intolerances to meal ingredients
- use of medications that could confound the study outcomes
- engaged in regular structured exercise >150 min per week
- alcohol use disorder
- premenopausal women
- persons who smoke
- prisoners
- inability to grant voluntary informed consent
Sites / Locations
- Washington University School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Experimental
Experimental
Experimental
Arm Label
Standard meal
High animal protein meal
High plant protein meal
High plant protein meal with additional leucine
Arm Description
Outcomes
Primary Outcome Measures
Monocyte p-S6 content
phospho-S6 content in monocytes
Secondary Outcome Measures
Full Information
NCT ID
NCT05235464
First Posted
January 18, 2022
Last Updated
March 16, 2023
Sponsor
Washington University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT05235464
Brief Title
High Protein Diet and Atherosclerosis
Acronym
HPA
Official Title
Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 13, 2023 (Actual)
Primary Completion Date
March 31, 2026 (Anticipated)
Study Completion Date
March 31, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas "lean" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atherosclerosis
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomized cross-over study
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard meal
Arm Type
Active Comparator
Arm Title
High animal protein meal
Arm Type
Experimental
Arm Title
High plant protein meal
Arm Type
Experimental
Arm Title
High plant protein meal with additional leucine
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Standard meal
Intervention Description
Standard meal
Intervention Type
Other
Intervention Name(s)
High animal protein meal
Intervention Description
Meal with high animal protein content
Intervention Type
Other
Intervention Name(s)
High plant protein meal
Intervention Description
Meal with high plant protein content
Intervention Type
Other
Intervention Name(s)
High plant protein meal with additional leucine
Intervention Description
Meal with high plant protein content and additional leucine
Primary Outcome Measure Information:
Title
Monocyte p-S6 content
Description
phospho-S6 content in monocytes
Time Frame
change from at 1 hour before meal intake and 3 hours after the meal
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
>=45 and <=75 years of age
body mass index >=25.0 and <40.0 kg/m2
Exclusion Criteria:
<45 and >75 years of age
body mass index <25.0 or >39.9 kg/m2
plasma triglyceride <125 mg/dl
history of or current significant organ system dysfunction
allergies or intolerances to meal ingredients
use of medications or dietary supplements that could confound the study outcomes
engaged in regular structured exercise >150 min per week
alcohol use disorder
premenopausal women
persons who smoke
prisoners
inability to grant voluntary informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bettina Mittendorfer, PhD
Phone
6186103465
Email
mittendb@wustl.edu
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brittney Mason
Email
brittneymason@wustl.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
High Protein Diet and Atherosclerosis
We'll reach out to this number within 24 hrs